However, a novel anti-HER2 therapy such as Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate targeting HER2, has recently been reported effective not only in HER2-positive but also in HER2-low breast cancer4, 5. This evidence concerns the gene ERBB2 and neoplasm.